Back to Browse Journals » Advances and Applications in Bioinformatics and Chemistry » Volume 1

A network biology approach evaluating the anticancer effects of bortezomib identifies SPARC as a therapeutic target in adult T-cell leukemia cells

Authors Junko H Ohyashiki, Ryoko Hamamura, Chiaki Kobayashi, Yu Zhang, Kazuma Ohyashiki

Published Date October 2008 Volume 2008:1 Pages 85—98

DOI http://dx.doi.org/10.2147/AABC.S4133

Published 30 October 2008

Junko H Ohyashiki1, Ryoko Hamamura2, Chiaki Kobayashi2, Yu Zhang2, Kazuma Ohyashiki2

1Intractable Immune System Disease Research Center, Tokyo Medical University, Tokyo, Japan; 2First Department of Internal Medicine, Tokyo Medical University, Tokyo, Japan

Abstract: There is a need to identify the regulatory gene interaction of anticancer drugs on target cancer cells. Whole genome expression profiling offers promise in this regard, but can be complicated by the challenge of identifying the genes affected by hundreds to thousands of genes that induce changes in expression. A proteasome inhibitor, bortezomib, could be a potential therapeutic agent in treating adult T-cell leukemia (ATL) patients, however, the underlying mechanism by which bortezomib induces cell death in ATL cells via gene regulatory network has not been fully elucidated. Here we show that a Bayesian statistical framework by VoyaGene® identified a secreted protein acidic and rich in cysteine (SPARC) gene, a tumor-invasiveness related gene, as a possible modulator of bortezomib-induced cell death in ATL cells. Functional analysis using RNAi experiments revealed that inhibition of the expression SPARC by siRNA enhanced the apoptotic effect of bortezomib on ATL cells in accordance with an increase of cleaved caspase 3. Targeting SPARC may help to treat ATL patients in combination with bortezomib. This work shows that a network biology approach can be used advantageously to identify the genetic interaction related to anticancer effects.

Keywords: network biology, adult T cell leukemia, bortezomib, SPARC

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely

Ohyashiki JH, Ohtsuki K, Mizoguchi I, Yoshimoto T, Katagiri S, Umezu T, Ohyashiki K

Drug Design, Development and Therapy 2014, 8:1151-1159

Published Date: 25 August 2014

Readers of this article also read:

Enzyme-responsive nanocomposites for wound infection prophylaxis in burn management: in vitro evaluation of their compatibility with healing processes

Grützner V, Unger RE, Baier G, Choritz L, Freese C, Böse T, Landfester K, Kirkpatrick CJ

International Journal of Nanomedicine 2015, 10:4111-4124

Published Date: 24 June 2015

Targeted delivery of polyamidoamine-paclitaxel conjugate functionalized with anti-human epidermal growth factor receptor 2 trastuzumab

Ma P, Zhang X, Ni L, Li J, Zhang F, Wang Z, Lian S, Sun K

International Journal of Nanomedicine 2015, 10:2173-2190

Published Date: 18 March 2015

Axillary dissection in primary breast cancer: variations of the surgical technique and influence on morbidity

Wojcinski S, Nuengsri S, Hillemanns P, Schmidt W, Deryal M, Ertan K, Degenhardt F

Cancer Management and Research 2012, 4:121-127

Published Date: 27 April 2012

Ranibizumab in the treatment of patients with visual impairment due to diabetic macular edema

Bandello F, De Benedetto U, Knutsson KA, Battaglia Parodi M, Cascavilla ML, Iacono P

Clinical Ophthalmology 2011, 5:1303-1308

Published Date: 14 September 2011

Investigational new drugs in the treatment of inflammatory bowel disease: a review

Imogen Williams, Jason Goh

Journal of Experimental Pharmacology 2011, 3:13-19

Published Date: 27 February 2011

Impact of topical bimatoprost 0.01% and bimatoprost 0.03% on conjunctival irritation in rabbits

Abayomi B Ogundele, Guangming Li, Joel J Ellis

Clinical Ophthalmology 2010, 4:77-80

Published Date: 15 February 2010

A simple method for assessing the strength of evidence for association at the level of the whole gene

David Curtis, Anna E Vine, Jo Knight

Advances and Applications in Bioinformatics and Chemistry 2008, 1:115-120

Published Date: 17 November 2008

Does titration of mitomycin C as an adjunct to trabeculectomy significantly influence the intraocular pressure outcome?

Susan J Lee, Augusto Paranhos, M Bruce Shields

Clinical Ophthalmology 2009, 3:81-87

Published Date: 25 September 2008

Evolution of a domain conserved in microtubule-associated proteins of eukaryotes

Alex S Rajangam, Hongqian Yang, Tuula T Teeri, Lars Arvestad

Advances and Applications in Bioinformatics and Chemistry 2008, 1:51-69

Published Date: 23 September 2008